{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T18:26:16Z","timestamp":1772994376288,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa Do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> The study aimed to evaluate the vancomycin and amikacin concentrations in serum and dialysate for automatic peritoneal dialysis (APD) patients<jats:bold>.<\/jats:bold><\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A total of 558 serum and dialysate samples of 12 episodes of gram-positive and 18 episodes of gram-negative peritonitis were included to investigate the relationship between vancomycin and amikacin concentrations in serum and dialysate on the first and third days of treatment. Samples were analysed 30, 120\u00a0min, and 48\u00a0h after intraperitoneal administration of vancomycin in peritonitis caused by gram-positive agents and 30, 120\u00a0min, and 24\u00a0h after intraperitoneal administration of amikacin in peritonitis caused by gram-negative agents. Vancomycin was administered every 72\u00a0h and amikacin once a day. The target therapeutic concentration of amikacin was 25\u201335\u00a0mg\/l at the peak moment and 4\u20138\u00a0mg\/l at the trough moment; and after 48\u00a0h for vancomycin, 15\u201320\u00a0mg\/l at the trough moment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> For peritonitis caused by gram-negative agents, at the peak moment, therapeutic levels of amikacin were reached in dialysate in 80.7% of patients with evolution to cure and in 50% of patients evaluated as non-cure (<jats:italic>p<\/jats:italic> = 0.05). At the trough moment, only 38% were in therapeutic concentrations in the dialysate in the cure group and 42.8% in the non-cure group (<jats:italic>p<\/jats:italic> = 1). Peak plasma concentrations were subtherapeutic in 98.4% of the samples in the cure group and in 100% of the non-cure group. At the trough moment, therapeutic concentrations were present in 74.4% of the cure group and 71.4% of the non-cure group (<jats:italic>p<\/jats:italic> = 1). Regarding vancomycin and among gram-positive agents, therapeutic levels were reached at the peak moment in 94% of the cure group and 6% of the non-cure group (<jats:italic>p<\/jats:italic> = 0.007). After 48\u00a0h, 56.8% of the cure group had a therapeutic serum concentration whereas for the non-cure group it was only 33.3% (<jats:italic>p<\/jats:italic> = 0.39).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Despite a small sample size, we demonstrated peak dialysate amikacin level and peak serum vancomycin level correlates well with Gram-negative and Gram positve peritonitis cure, respectively. It is suggested to study the antibiotics pharmacodynamics for a better understanding of therapeutic success in a larger sample.<\/jats:p>","DOI":"10.3389\/fphar.2021.658014","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:21:36Z","timestamp":1622200896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis"],"prefix":"10.3389","volume":"12","author":[{"given":"P\u00e2mela","family":"Falbo dos Reis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasqual","family":"Barretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laudilene","family":"Marinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre Lu\u00eds","family":"Balbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Awdishu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/ndt\/gfr274","article-title":"Use of Aminoglycosides for Peritoneal Dialysis-Associated Peritonitis Does Not Affect Residual Renal Function","volume":"27","author":"Badve","year":"2012","journal-title":"Nephrol. Dial. Transpl."},{"key":"B2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2165\/00003088-199222040-00005","article-title":"Prediction of Serum Vancomycin Concentrations Following Intraperitoneal Loading Doses in Continuous Ambulatory Peritoneal Dialysis Patients with Peritonitis","volume":"22","author":"Bailie","year":"1992","journal-title":"Clin. Pharmacokinet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e3178010","DOI":"10.1371\/journal.pone.0031780","article-title":"Peritoneal Dialysis-Related Peritonitis Due to Staphylococcus aureus: A Single-center Experience over 15 Years","volume":"7","author":"Barretti","year":"2012","journal-title":"PLoS ONE"},{"key":"B3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/089686080702700324","article-title":"Peritonitis in Latin America","volume":"27","author":"Barretti","year":"2007","journal-title":"Perit Dial. Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/ndt\/gfm079","article-title":"Single UK centre Experience on the Treatment of PD Peritonitis-Aantibiotic Levels and Outcomes","volume":"22","author":"Blunden","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3747\/pdi.2010.00185","article-title":"Peritoneal Dialysis-Associated Peritonitis Rates and Outcomes in a National Cohort Are Not Improving in the Post-Millennium (2000 - 2007)","volume":"31","author":"Brown","year":"2011","journal-title":"Perit Dial. Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3747\/pdi.2012.00333","article-title":"Novel Predictors of Peritonitis-Related Outcomes in the BRAZPD Cohort","volume":"34","author":"de Moraes","year":"2012","journal-title":"Perit Dial. Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3747\/pdi.2010.00294","article-title":"Intraperitoneal Vancomycin Concentrations during Peritoneal Dialysis-Associated Peritonitis: Correlation with Serum Levels","volume":"32","author":"Fish","year":"2012","journal-title":"Perit Dial. Int."},{"key":"B9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1017\/s0022215100124132","article-title":"Gentamicin Ototoxicity in Continuous Ambulatory Peritoneal Dialysis","volume":"107","author":"Gendeh","year":"1993","journal-title":"J. Laryngol. Otol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11255-014-0763-5","article-title":"Predictors for and Impact of High Peritonitis Rate in Taiwanese Continuous Ambulatory Peritoneal Dialysis Patients","volume":"47","author":"Hsieh","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/sj.ki.5000257","article-title":"Non-pseudomonas Gram-Negative Peritonitis","volume":"69","author":"Jain","year":"2006","journal-title":"Kidney Int."},{"key":"B12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1525-139x.2011.00883.x","article-title":"Do antibiotic Levels Need to Be Followed in Treating Peritoneal Dialysis-Associated Peritonitis?","volume":"24","author":"Johnson","year":"2011","journal-title":"Semin. Dial."},{"key":"B13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/089686080202200508","article-title":"Predictors of Outcome Following Bacterial Peritonitis in Peritoneal Dialysis","volume":"22","author":"Krishnan","year":"2002","journal-title":"Perit Dial. Int."},{"key":"B14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1177\/0896860819889774","article-title":"Vancomycin in Peritoneal Dialysis: Clinical Pharmacology Considerations in Therapy","volume":"40","author":"Lam","year":"2020","journal-title":"Perit Dial. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3747\/pdi.2016.00078","article-title":"ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment","volume":"36","author":"Li","year":"2016","journal-title":"Perit Dial. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3747\/pdi.2018.00209","article-title":"Review of Antibiotic Dosing with Peritonitis in APD","volume":"39","author":"Mancini","year":"2019","journal-title":"Perit Dial. Int."},{"key":"B17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1128\/aac.31.2.173","article-title":"Comparative Study of Intraperitoneal and Intravenous Vancomycin Pharmacokinetics during Continuous Ambulatory Peritoneal Dialysis","volume":"31","author":"Morse","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/0272-6386(95)90132-9","article-title":"Trough Serum Vancomycin Levels Predict the Relapse of Gram-Positive Peritonitis in Peritoneal Dialysis Patients","volume":"25","author":"Mulhern","year":"1995","journal-title":"Am. J. Kidney Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2147\/ijnrd.s123618","article-title":"Peritoneal Dialysis-Related Peritonitis: Challenges and Solutions","volume":"11","author":"Salzer","year":"2018","journal-title":"Int. J. Nephrol. Renovasc Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/s0272-6386(99)70102-2","article-title":"Effect of Aminoglycoside Use on Residual Renal Function in Peritoneal Dialysis Patients","volume":"34","author":"Shemin","year":"1999","journal-title":"Am. J. Kidney Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3747\/pdi.2016.00120","article-title":"ISPD Catheter-Related Infection Recommendations: 2017 Update","volume":"37","author":"Szeto","year":"2017","journal-title":"Perit Dial. Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3747\/pdi.2012.00318","article-title":"The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis","volume":"34","author":"Tang","year":"2014","journal-title":"Perit Dial. Int."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.658014\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:21:38Z","timestamp":1622200898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.658014\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":22,"alternative-id":["10.3389\/fphar.2021.658014"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.658014","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"article-number":"658014"}}